#870
Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials
Introduction:
Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Authors:
Wheeler D,
Kulke M,
O’Dorisio T,
Hörsch D,
Jackson S,
Keywords:
carcinoid,
heart disease,
serotonin,
telotristat,
#849
Patient-Reported Symptom Experiences Following Participation in a Study of Telotristat Etiprate for Patients with Neuroendocrine Tumors and Diarrhea Not Adequately Controlled on Octreotide
Introduction:
Telotristat etiprate (LX1606), an oral tryptophan hydroxylase (TPH) inhibitor, was recently evaluated in a dose-escalation (DE) study in patients (pts) with carcinoid tumors and diarrhea not adequately controlled on octreotide.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Kulke M
Authors:
Kulke M,
O’Dorisio T,
Yang Q,
Jackson J,
Jackson S,
Keywords:
carcinoid,
interview,
symptom improvement,
#131
Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction:
Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Kvols L
Authors:
Kvols L,
Wiedenmann B,
Öberg K,
Mohideen P,
O’Dorisio T,
Keywords:
Pasireotide,
SOM230,
octreotide,
carcinoid,
diarrhea,
flushing,
efficacy ,
